Yamamoto, Hiroshi

写真a

Affiliation

Research Centers and Institutes, Office for Open Innovation （Mita）

Position

Project Professor (Non-tenured)
Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士（薬学）, The University of Tokyo, Coursework, 1989.03

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 薬剤師, 1985

Page Top ▲
 

Papers 【 Display / hide 】

  • Plasma Branched-Chain and Aromatic Amino Acids in Relation to Hypertension

    M H Mahbub 1, Natsu Yamaguchi 1, Ryosuke Hase 1, Hidekazu Takahashi 2, Yasutaka Ishimaru 1, Rie Watanabe 1, Hiroyuki Saito 1, Junki Shimokawa 1, Hiroshi Yamamoto 3, Shinya Kikuchi 3, Tsuyoshi Tanabe 1

    Nutrients  12 （ 12 ） 3791 2020.12

    Research paper (scientific journal), Joint Work, Accepted

    　View Summary

    Findings of the available studies regarding the roles of branched-chain amino acids (BCAAs) and aromatic amino acids (AAAs) in hypertension are inconsistent, conflicting and inconclusive. The purpose of this study was to explore and clarify the existence of any relationships of individual BCAAs and AAAs with hypertension with adjustments for potential relevant confounders. A total of 2805 healthy controls and 2736 hypertensive patients were included in the current analysis. The associations between individual amino acids and hypertension were explored by logistic regression analyses adjusted for potential confounding variables. Among the investigated amino acids, only the BCAAs showed consistently significant positive associations with hypertension in the adjusted models (p-trend < 0.05 to 0.001). However, compared with the corresponding lowest quartile of individual BCAAs, the positive association with hypertension remained significant only in the highest quartile (p < 0.01 to 0.001). We confirmed in a relatively large cohort of subjects that BCAAs, not AAAs, demonstrated consistent positive associations with hypertension. The results display the promising potential for the use of BCAAs as relevant and accessible biomarkers, and provide perspectives on interventions directed towards the reduction in plasma BCAA levels in the prevention and management of hypertension.

    Keywords: plasma amino acids, branched-chain, aromatic, hypertension

  • Preoperative AminoIndex Cancer Screening (AICS) abnormalities predict postoperative recurrence in patients undergoing curative resection for non-small cell lung cancer.

    Higashiyama M, Miyazaki R, Yamamoto H, Anayama T, Kikuchi S, Hirohashi K, Okami J, Maniwa T, Kimura T, Orihashi K, Imamura F.

    BMC Cancer 20   1100 2020.11

    Research paper (scientific journal), Joint Work, Accepted

    　View Summary

    Background
    AminoIndex™ Cancer Screening (AICS (lung)) was developed as a screening test for lung cancer using a multivariate analysis of plasma-free amino acid (PFAA) profiles. According to the developed index composed of PFAA, the probability of lung cancer was categorized into AICS (lung) ranks A, B, and C in order of increasing risk. The aim of the present study was to investigate the relationship between the preoperative AICS (lung) rank and surgical outcomes in patients who underwent curative resection for non-small cell lung cancer (NSCLC).

    Methods
    Preoperative blood samples were collected from 297 patients who underwent curative resection for NSCLC between 2006 and 2015. PFAA concentrations were measured. The relationship between the preoperative AICS (lung) rank and clinicopathological factors was examined. The effects of the preoperative AICS (lung) rank on postoperative outcomes were also analyzed.

    Results
    The AICS (lung) rank was A in 93 patients (31.3%), B in 82 (27.6%), and C in 122 (41.1%). The AICS (lung) rank did not correlate with any clinicopathological factors, except for age. Based on follow-up data (median follow-up period of 6 years), postoperative recurrence was observed in 22 rank A patients (23.7%), 15 rank B (18.3%) and 49 rank C (40.2%). In the univariate analysis, preoperative AICS (lung) rank C was a worse factor of recurrence-free survival (p = 0.0002). The multivariate analysis identified preoperative AICS (lung) rank C (HR: 2.17, p = 0.0005) as a significant predictor of postoperative recurrence, particularly in patients with early-stage disease or adenocarcinoma.

    Conclusion
    Preoperative AICS (lung) rank C is a high-risk predictor of postoperative recurrence in patients undergoing curative resection for NSCLC.

  • A multicentre clinical validation of AminoIndex Cancer Screening (AICS)

    Mikami H., Kimura O., Yamamoto H., Kikuchi S., Nakamura Y., Ando T., Yamakado M.

    Scientific Reports （Scientific Reports)  9 （ 1 ）  2019.12

    Research paper (scientific journal), Joint Work, Accepted

    　View Summary

    © 2019, The Author(s). AminoIndex Cancer Screening (AICS) is a novel cancer screening test based on plasma free amino acid (PFAA) levels. This system categorises subjects as rank A, B, or C in order of increasing probability of each cancer incidence. The current study aimed to validate the potential of AICS for cancer detection. AICS values were determined from the PFAA levels in subjects examined at Chiba Cancer Center Cohort, Mitsui Memorial Hospital, and Saihaku Hospital, and the cancer incidence was investigated. The sensitivities of rank C for cancer diagnosis within 1 year after AICS examination were 83.3% (10/12) for gastric, 50.0% (2/4) for lung, 46.2% (6/13) for colorectal, 50.0% (8/16) for prostate, 43.8% (7/16) for breast, and 50.0% (1/2) for uterine/ovarian cancer. The total cancer detection rate via AICS was 0.33% (34/10,245). The sensitivities during the maximum follow-up period of 6.2 years were 51.7% (15/29) for gastric, 18.2% (2/11) for lung, 28.6% (8/28) for colorectal, 36.4% (8/22) for prostate, 29.0% (9/31) for breast, and 33.3% (2/6) for uterine/ovarian cancers. In conclusion, AICS is a more useful method for evaluating the probability of cancer incidence than for predicting onset, suggesting that annual AICS should be recommended to detect any malignancy.

  • Relationship of reduced glomerular filtration rate with alterations in plasma free amino acids and uric acid evaluated in healthy control and hypertensive subjects

    Mahbub M.H., Yamaguchi N., Takahashi H., Hase R., Yamamoto H., Kikuchi S., Tanabe T.

    Scientific Reports （Scientific Reports)  9 （ 1 ）  2019.12

    Research paper (scientific journal), Joint Work, Accepted

    　View Summary

    © 2019, The Author(s). The potential association between altered levels of plasma free amino acids (PFAAs) and uric acid (UA) with estimated glomerular filtration rate (eGFR) remains unknown among patients with hypertension. A total of 2804 healthy controls and 2455 hypertensive patients were included in the current analysis. eGFR was defined as reduced when it was <60 ml/min/1.73 m2. The associations between reduced eGFR and individual PFAAs and UA in the healthy control and hypertension groups were explored by logistic regression analyses adjusted for potential confounding variables. Results show that UA had a significant positive association with reduced eGFR in both healthy control and hypertension groups (P < 0.001). Among the PFAAs, citrulline, glycine and phenylalanine showed significant positive associations with reduced eGFR in both healthy control (P < 0.01 to 0.001) and hypertension (P < 0.001) groups. Moreover, alanine, asparagine and methionine achieved significant positive associations with reduced eGFR only in the hypertension group (P < 0.01 to 0.001). Conversely, serine showed significant inverse associations with reduced eGFR in the hypertension group only (P < 0.001). Our findings provide first evidence for a strong relationship between distinct patterns of PFAAs and elevated UA with reduced eGFR in hypertension. The findings may appear useful in developing effective strategies for the prevention or early detection and treatment of declined kidney function in hypertension.

  • Diagnostic yield of the plasma free amino acid index for pancreatic cancer in patients with diabetes mellitus

    Mizuno S., Isayama H., Nakai Y., Ishigaki K., Saito K., Sato T., Takeda T., Hakuta R., Saito T., Takahara N., Kogure H., Ijichi H., Tateishi K., Tada M., Shikata N., Tagami T., Kikuchi S., Yamamoto H., Yamakado M., Koike K.

    Pancreatology （Pancreatology)  19 （ 5 ） 695 - 698 2019.07

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  14243903

    　View Summary

    © 2019 IAP and EPC Objectives: A multivariate index calculated using plasma free amino acids (PFAA index) was reported as a diagnostic biomarker for pancreatic cancer (PaC). Although diabetes mellitus (DM) is expected to be an early diagnostic indicator of PaC, identifying the high-risk individuals among patients with DM is warranted. We evaluated the diagnostic yield of the PFAA index for PaC in patients with DM. Methods: We compared the diagnostic yield of the PFAA index between individuals with and those without DM. Cases and controls were recruited prospectively, and controls were matched to cases at a 1:1 ratio for age, sex, and DM status. Results: A total of 180 case–control pairs were included in the analysis. The prevalence of DM was 53.3%. The sensitivity of the PFAA index was 66.7% in cases with DM and 56.0% in those without DM (P = 0.14), and the specificity was 92.7% in controls with DM and 94.0% in those without DM (P = 0.95). Conclusions: This matched case-control study revealed a comparable diagnostic yield of the PFAA index for PaC in individuals with and those without DM. The PFAA index can be used as a biomarker for further diagnostic imaging in selected patients with DM.

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • アミノインデックス®がんリスクスクリーニング（AICS®）の健診におけるエビデンスと検査特性

    山本浩史

    Precision Medicine 3 ( 3 ) 44 - 50 2020

    Article, review, commentary, editorial, etc. (other), Single Work

  • 血漿アミノ酸プロファイルに基づくがんスクリーニング

    東江咲乃、山本浩史、野口恭志

    血液フロンティア 26 ( 10 ) 23 - 32 2016

    Article, review, commentary, editorial, etc. (other), Joint Work

Page Top ▲

Presentations 【 Display / hide 】

  • Plasma amino acid profile-based index, derived from AMINOINDEX TECHNOLOGY, as a novel recurrence biomarker in gynecological adenocarcinoma patients with negative existing tumor marker levels.

    Suzuki Y, Tokinaga-Uchiyama A, Mizushima T, Maruyama Y, Mogami T, Shikata N, Ikeda A, Yamamoto H, Miyagi E.

    17th Biennial Meeting of the International Gynecological Cancer Society, 

    2018.09
    , 

    Poster presentation

  • Clinical application of a novel cancer screening test, AminoIndexTM Cancer Screening.

    Yamakado M, Yamamoto H.

    The 11th Annual World Cancer Congress 2018, 

    2018.05
    , 

    Oral presentation (general)

  • Alterations of plasma glutamine and surgical stress in gastric cancer surgery.

    Hayashi T, Aoyama T, Yamamoto H, Yamada T, Sato T, Rino Y, Masuda M, Cho H, Tsuburaya A, Ogata T, Yoshikawa T.

    2018 Gastrointestinal Cancer Symposium (ASCO-GI), 

    2018.01
    , 

    Poster presentation

  • Changes between pre- and post-operative AICS(lung) in NSCLC patients: Predictability of high-risk cases with recurrence.

    Higashiyama M, Anayama T, Okami Jiro, Tokunaga T, Yamamoto H, Kikuchi S, Ikeda A, Orihashi K, Imamura F.

    18th World Conference on Lung Cancer (WCLC), 

    2017.10
    , 

    Poster presentation

  • A novel cancer screening test, AminoIndexTM Cancer Screening and its clinical application.

    Yamakado M, Kikuchi S, Yamamoto M, Yamamoto H.

    The 10th Annual World Cancer Congress 2017, 

    2017.05
    , 

    Oral presentation (general)

display all >>

Page Top ▲